Ibex Breast Suite

Ibex Breast Suite is an end-to-end AI-powered diagnostic support platform developed by IBEX for breast pathology laboratories. Designed for pathologists working with both biopsies and excisions, it replaces fragmented point tools with a single integrated solution covering H&E analysis and IHC quantification. By automating the search for tissue findings and standardising biomarker scoring, Ibex Breast enables labs to deliver faster, more accurate results while elevating patient care.

The platform is built around three core pillars: accuracy — identifying multiple findings including small, hard-to-find foci such as microinvasion and lymphovascular invasion (LVI); reproducibility — increasing consistency through objective IHC quantification and scoring; and efficiency — reducing review times by up to 43%, decreasing diagnostic IHC orders, and enabling pre-read IHC ordering to reduce turnaround time.

Ibex Breast H&E — Precision AI for Breast Pathology

• Recognises more than 50 malignant and benign tissue morphologies, delivering granular insights that eliminate tedious manual reviews.
• Detection capabilities include microinvasion, microcalcification, LVI, IDC vs ILC differentiation, DCIS grading, lobular neoplasia, tumour-infiltrating lymphocytes (TILs), and more.
• Demonstrated high diagnostic accuracy in clinical validation studies, with diagnostic accuracy improving from 97% to 100% when pathologists used the tool, and detection of 97.6% of microinvasive cases.
• Exceptionally robust performance validated across multiple laboratories, scanners, and patient demographics.
• Reduces review time compared to manual review and decreases diagnostic IHC orders by approximately 30%.

Ibex Breast HER2 — Objective Scoring with "Zero-Click" Efficiency

• Automates 2023 ASCO/CAP HER2 scoring guidelines, removing subjectivity and ensuring reproducible precision for every patient.
• Identifies HER2-low and HER2-ultralow cases with confidence.
• "Zero-click" invasive tumour detection that automatically excludes ductal carcinoma in situ (DCIS).
• Automated tumour cell identification and cell staining pattern classification.
• Interactive invasive contours with score recalculation capability.
• Visualisation of AI findings and quantification of cell staining pattern percentages for transparent understanding of score results.
• Validated in an early evidence programme spanning 14 international cancer centres and laboratories, covering a diverse cohort of 2,300 breast cancer biopsies and excisions, demonstrating improved scoring accuracy and consistency.
• Robust performance validated across multiple labs, scanners, and patient demographics.

Ibex Breast ER/PR — Standardised ER/PR Quantification

• Delivers automated ER/PR quantification aligned with ASCO/CAP 2020 guidelines, delineating expression into positive and negative categories.
• "Zero-click" invasive tumour detection, automatically excluding DCIS.
• Automated tumour cell identification and cell staining pattern classification.
• Interactive invasive contours with score recalculation.
• Visualisation of AI findings and quantification of staining pattern percentages for explainable results.
• Robust clinical validation conducted at multiple laboratories demonstrates enhanced reproducibility, scoring precision, and interobserver concordance for ER/PR IHC scoring.

Ibex Breast Ki67 — Precision Proliferation Assessment

• Replaces manual counting with AI-powered quantification aligned with International Ki67 Working Group and St. Gallen guidelines.
• "Zero-click" invasive tumour detection, automatically excluding DCIS.
• Automated tumour cell identification and cell staining pattern classification.
• Interactive invasive contours with score recalculation.
• Visualisation of AI findings and quantification of staining pattern percentages for accurate, reproducible patient stratification.
• Multi-laboratory clinical validation demonstrates enhanced reproducibility, scoring precision, and interobserver concordance for Ki67 IHC scoring.

Ibex Lymph Node — Elevating Lymph Node Metastasis Detection

• Designed to transform the time-intensive, meticulous search for lymph node metastases from manual screening to automated review.
• Empowers pathologists to detect metastases faster while removing the repetitive strain of searching for isolated tumour cells.
• Currently under development and coming soon.

Clinical and Operational Impact

• Review time reduced by up to 43% compared to manual review workflows.
• Diagnostic accuracy improved from 97% to 100% in pathologist-assisted studies.
• AI detected 97.6% of microinvasive cases in clinical validation.
• Approximately 30% decrease in diagnostic IHC orders when used in routine practice.
• Validated across multiple international laboratories, scanners, and diverse patient demographics.
• Supported by a broad body of peer-reviewed publications and conference presentations, including studies in NPJ Breast Cancer, JCO Precision Oncology, ESMO Open, Clinical Breast Cancer, and a Nature journal publication from Institut Curie.

Ibex Breast Suite includes solutions that are CE-IVD certified and registered with MHRA (UK), TGA (Australia), ANVISA (Brazil), AMAR (Israel), and Swissmedic (Switzerland). One solution is FDA cleared in the United States, while others are available as Research Use Only (RUO). The platform is designed to integrate into existing pathology workstation workflows, supporting both primary diagnosis and second-opinion use cases across a wide range of laboratory settings.